Not provided
Not provided
Not provided
Not provided
Not provided
assessment of project in wake of covid-19 related interruptions
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Nathan Kline Institute for Psychiatric Research | OTHER |
| American Foundation for Suicide Prevention | OTHER |
Not provided
Not provided
Not provided
The purpose of this study is to test the potential of the rapid-acting anti-depressant ketamine to decrease suicidality in Borderline Personality Disorder (BPD).
The rate of completed suicide in BPD is similar to that of depression or schizophrenia. There is currently no specific medication treatment for BPD.
Ketamine is an FDA-approved anesthetic agent that has been shown to rapidly decrease suicidality and improve mood in people with Major Depressive Disorder (MDD). Though symptoms overlap, effective treatments for MDD and BPD differ. This clinical trial tests if ketamine also decreases suicidality and improves mood in BPD.
This trial will also measure several other outcomes after ketamine versus placebo in BPD: adverse events, BPD symptoms, pain, social cognition, and neuroplasticity.
This clinical trial primarily tests the impact of ketamine on suicidal thoughts in Borderline Personality Disorder (BPD). It also tests the impact of ketamine on symptom intensity (for mood, BPD, and pain symptoms), social cognition, and neuroplasticity in people with BPD.
Suicidal ideation and action are too common in BPD, occurring at rates similar to those in people with depression or schizophrenia. Intensive psychotherapy helps, but many people with BPD do not have access to that treatment, and not everyone responds to psychotherapy if they do get access. No medication is FDA-approved for BPD, and no medication has been shown to decrease suicidality in BPD.
Ketamine is a promising medication for this problem. It is an FDA-approved anesthetic medication with N-methyl D-aspartate activity. Sub-anesthetic doses of ketamine decrease suicidality and improve mood in people with Major Depressive Disorder (MDD). This effect is rapid, with symptom improvement within hours that endures approximately two weeks. People with BPD can have symptoms that overlap with those of MDD, however, the effective treatments for BPD and MDD differ. This clinical trial will test if ketamine, which is effective in MDD, is also effective in BPD.
The investigators will use semi-structured interviews and self-report questionnaires to measure suicidal ideation and clinical symptoms (adverse events, mood symptoms, BPD symptoms, and pain). Social cognition will be also be measured using both interviews/questionnaires and cognitive psychology tasks.
One proposed mechanism of ketamine's effect in MDD is increased neuroplasticity - opening a window during which new learning can occur. This mechanism has been demonstrated in rodent models of depression. In BPD, negatively-biased social interpretations impede meaningful recovery and increase suicide risk over time. A post-ketamine neuro-plastic window may provide an opportunity for revisions of rigid social attributions. The investigators will test for changes in neuroplasticity using a cognitive psychology task and electro-encephalography.
Baseline measures of demographics, life experiences, and symptoms may also be used to predict outcomes or as co-variates in our analyses.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| midazolam | Placebo Comparator | Midazolam IV; 0.04mg/kg over 40 minutes |
|
| low dose ketamine | Active Comparator | ketamine IV; 0.5 mg/kg over 40 minutes |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ketamine | Drug | 1 single dose of IV ketamine |
| |
| Midazolam |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Suicidal Thoughts as Measured by Item 10 on the Montgomery-Asberg Depression Scale (MADRS) | The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms. Scores are averaged across items and can range from 0 to 6 (with 0 indicating enjoying life, and 6 indicating explicit plans for suicide). Outcome description updated when results were entered. | Timepoints will be baseline, 1hr post-infusion and at 1, 3, 7, 14, & 28 days after infusion. |
| Change in Suicidality as Measured by the Columbia Suicide Severity Rating Scale (C-SSRS) | Suicide Rating Scale from 1-5; higher numbers indicate increased suicidal thinking. | Timepoints will be baseline, 1hr post-infusion and at 1, 3, 7, 14, & 28 days after infusion. |
| Change in Suicidality as Measured by Item-12 on the Quick Inventory of Depressive Symptomatology (QIDS SR-16) | The Quick Inventory of Depressive Symptomatology (QIDS SR-16) is a a self-report measure of depression. Each item is scored from 0-3. Higher scores denote more severe load of depressive symptoms. Item 12 measures thoughts of death or suicide from 0 (no thoughts) to 3 (specific suicide plan or action.). Presented is the mean score across items with a range of 0 to 3 where the higher score indicates greater depressive symptoms. Outcome description was updated at the time of results entry. | Timepoints will be baseline, 1hr post-infusion and at 1, 3, 7, 14, & 28 days after infusion. |
| Change in Suicidality as Measured by Item 9 on Beck Depression Inventory | When the test is scored, a value of 0 to 3 is assigned for each answer and then the total score is used to quantify the participant's degree of depression from 0 = no depression to 63 = maximally severe depression. Item 9 measures degree of suicidal thoughts or wishes from 0 = no thoughts to 3 = suicidal intent. | Timepoints will be baseline, 1hr post-infusion and at 1, 3, 7, 14, & 28 days after infusion. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score | The MADRS scale measures the depression level of a participant. The total score was derived by adding the scores of the following 10 items: 1, Apparent sadness; 2, Reported sadness; 3, Inner tension; 4, Reduced sleep; 5, Reduced appetite; 6, Concentration difficulties; 7, Lassitude; 8, Inability to feel; 9, Pessimistic thoughts; 10, Suicidal thoughts. Each item was scored using a scale of 0 to 6 (a higher score indicates increased severity). The maximum total score is 60; 0, no depression; 60, severely depressed. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Bias Scores on the Implicit Association Tests (IAT) of Death, Escape and Self Harm Imagery. | The Implicit Association Test measures implicit automatic associations by tracking the speed at which participants associate different groups of words. The scale is delivered electronically using an open-source software. Three distinct IATs will be administered to assess participant's implicit associations with death, escape, and self harm imagery respectively. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sarah Fineberg, MD/PhD | Yale University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Connecticut Mental Health Center | New Haven | Connecticut | 06519 | United States | ||
| Yale New Haven Hospital |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Midazolam | Midazolam IV; 0.04mg/kg over 40 minutes Midazolam: 1 single dose of IV midazolam |
| FG001 | Low Dose Ketamine | ketamine IV; 0.5 mg/kg over 40 minutes Ketamine: 1 single dose of IV ketamine |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Midazolam | Midazolam IV; 0.04mg/kg over 40 minutes Midazolam: 1 single dose of IV midazolam |
| BG001 | Low Dose Ketamine | ketamine IV; 0.5 mg/kg over 40 minutes Ketamine: 1 single dose of IV ketamine |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change in Suicidal Thoughts as Measured by Item 10 on the Montgomery-Asberg Depression Scale (MADRS) | The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms. Scores are averaged across items and can range from 0 to 6 (with 0 indicating enjoying life, and 6 indicating explicit plans for suicide). Outcome description updated when results were entered. | Intention to treat. | Posted | Least Squares Mean | Standard Error | units on a scale | Timepoints will be baseline, 1hr post-infusion and at 1, 3, 7, 14, & 28 days after infusion. |
|
Uo to 28 days
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Midazolam | Midazolam IV; 0.04mg/kg over 40 minutes Midazolam: 1 single dose of IV midazolam |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Vivid dreams | Nervous system disorders | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Sarah Fineberg, MD, PhD | Yale School of Medicine | (203) 974-7265 | sarah.fineberg@yale.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Oct 19, 2021 | May 4, 2023 | Prot_SAP_000.pdf |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001883 | Borderline Personality Disorder |
| D013405 | Suicide |
| ID | Term |
|---|---|
| D010554 | Personality Disorders |
| D001523 | Mental Disorders |
| D016728 | Self-Injurious Behavior |
| D001526 | Behavioral Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D007649 | Ketamine |
| D008874 | Midazolam |
| ID | Term |
|---|---|
| D003510 | Cyclohexanes |
| D003516 | Cycloparaffins |
| D006840 | Hydrocarbons, Alicyclic |
| D006844 | Hydrocarbons, Cyclic |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
1 single dose of IV midazolam |
|
| Timepoints will be baseline, 1hr post-infusion and at 1, 3, 7, 14, & 28 days after infusion. |
| Change in Beck Depression Inventory Score | The Beck Depression Inventory (BDI) consisted of twenty-one questions about how the subject has been feeling in the last week. Each question has a set of at least four possible answer choices, ranging in intensity. When the test is scored, a value of 0 to 3 is assigned for each answer and then the total score is used to quantify the participant's degree of depression from 0 = no depression to 63 = maximally severe depression. | Timepoints will be baseline, 1hr post-infusion and at 1, 3, 7, 14, & 28 days after infusion. |
| Change in Beck Anxiety Inventory Score | The Beck Anxiety Inventory (BDI) consisted of twenty-one questions about how the subject has been feeling in the last week. Each question has a set of at least four possible answer choices, ranging in intensity. When the test is scored, a value of 0 to 3 is assigned for each answer and then the total score is used to quantify the participant's degree of anxiety from 0 = no anxiety to 63 = maximally severe anxiety. | Timepoints will be baseline, 1hr post-infusion and at 1, 3, 7, 14, & 28 days after infusion. |
| Change in Zanarini Rating Scale for Borderline Personality Disorder | A dimensional self-report measure of BPD symptoms that consists of 9 items scored on a 4 point likert scale. Scores range of 0 = minimally symptomatic to 28 = maximally symptomatic for symptoms of Borderline Personality Disorder. Originally, 1hr post-infusion was included as a time frame but this was not collected at this time frame. | Timepoints will be baseline and at 1, 3, 7, 14, & 28 days after infusion. |
| Change in Preferred Distance in Stop-distance Paradigm (SDP) | The stop-distance paradigm is a measure of preferred interpersonal distance (PID). Subjects begin the task standing face-to-face and 6 feet away from a test confederate. On each of 3 trials, the confederate slowly approaches the subject. The subjects are instructed to say "stop" to indicate their 1) preferred conversational distance, then a closer distance 2) "if you start to feel uncomfortable". After each "stop", toe to toe distance is measured using a tape measure, and mean PID for the three trials is computed separately for conversational and uncomfortable distance. A computerized version of the task may also be implemented for remote visits and administered in place of the in-person task. | Timepoints will be at baseline and 3, 7, 14, 28 days after infusion |
| Change in Behavior in the Economic Trust Game - Cooperation | The trust game is a multi-round economic exchange game. There are two roles in the game: investor and trustee. Study participants will play as the trustee. Each round, the investor is given a set number of points and can send any amount to the trustee. The investment triples and the trustee decides how much to repay the investor. Outcome measures are cooperation (amount returned to the investor) and coaxing (amount returned to investor on trials when poor prior returns from trustee have led investor to decrease investment). Cooperation was used as part of the evaluation in this study- coaxing was not. Outcome measure description was updated at the time of results entry. | Timepoints will be at baseline and 3, 7, 14, 28 days after infusion |
| Change in Social Adjustment Scale Self Report (SAS-SR) Short Version Score | This questionaire measures expressive and instrumental performance over the past two weeks in six role areas: (1) work, either as a paid worker, unpaid homemaker, or student, (2) social and leisure activities, (3) relationships with extended family, (4) role as a marital partner, (5) parental role, and (6) role within the family unit, including perceptions about economic functioning.Each question is rated on a five-point scale from which role area means and an overall mean can be obtained, with higher scores denoting greater impairment. Role areas not relevant to the respondent can be skipped. Overall means are based on all items completed by the respondent. Scores range from 0 = no difficulties to 125 = broad difficulties in multiple domains. An overall adjustment | Timepoints will be at baseline and 3, 7, 14, 28 days after infusion |
| Change in Brief Pain Inventory Score - Intensity | Self report inventory that assesses intensity of pain and its interference with everyday life. Intensity: pain severity as measured by a 0 to 10 visual analogue scale. 0 = no pain, 10 = worst pain imaginable. Interference score: Interference as measured by a 0 to 10 numerical rating scale. 0 = does not interfere, 10 = completely interferes | Timepoints will be at baseline, and post-infusion 1hr, and days 1, 3, 7, 14, & 28. |
| Change in Brief Pain Inventory Score - Interference | Self report inventory that assesses intensity of pain and its interference with everyday life. Intensity: pain severity as measured by a 0 to 10 visual analogue scale. 0 = no pain, 10 = worst pain imaginable. Interference score: Interference as measured by a 0 to 10 numerical rating scale. 0 = does not interfere, 10 = completely interferes | Timepoints will be at baseline, and post-infusion 1hr, and days 1, 3, 7, 14, & 28. |
| Change in Clinician-Administered Dissociative States Scale (CADSS) Score | This scale captures the range of possible subjective side effects of ketamine or Midazolam. This consists of 23 questions and scores for each question range from 0-4. The maximum score is 92 with higher scores indicating more dissociative symptoms. | Timepoints: pre- infusion, during infusion +20, +40 minutes, and post-infusion 40 minutes. |
| Change in Adverse Events | Adverse events were tracked in a log of treatment emergent adverse events, EKG, pulse oximetry, vital signs. A count of any treatment emergent adverse events is presented through Day 28. The outcome measure description as updated when results were entered. | Timepoints: Continuous monitoring throughout infusion; post-infusion days 1, 3, 7, 14, 28. |
| Change in 'Reading the Mind in the Eyes' Test (RMET) Score | The RMET is an advanced test of theory of mind. It is widely used to assess individual differences in social cognition and emotion recognition across different groups and cultures. This is a score from 0-36 where higher score indicates better performance. | Timepoints: at baseline and 3, 7, 14, 28 days after infusion. |
| Change in Brief Psychiatric Rating Scale (BPRS) Total Scores | BPRS is an 18-item clinician rated scale with 11 general symptom items, 5 positive-symptom items, and 2 negative symptom items scored on a 7-point scale (1=not present and 7=extremely severe), with higher score indicating greater severity of symptom. Total possible score range=18 to 126. | Timepoints: pre-infusion, during infusion +20, +40 minutes, post-infusion +40 minutes |
| Change in Beck Suicide Scale Total Score | The Beck Suicide Scale is a 23 item self report scale with items to specifically assess the presence and intensity of thoughts and actions related to suicidality. Each item response is on a 3 point likert (0-2) for each of 21 items, so possible totals range from 0-42. Higher scores indicate higher suicidality. The description was updated when results were entered. | Timepoints will be baseline, 1hr post-infusion and at 1, 3, 7, 14, & 28 days after infusion. |
| Timepoints: at baseline and 1, 3, 7, 28 days after infusion. |
| Change in Resting State Electroencephalography (EEG) | measurement of electrical patterns in the brain while subject is at rest with eyes open looking at fixation cross | Timepoints: at baseline and 1 and/or 7 days after infusion. |
| Change in Electroencephalography (EEG) Signal During Behavioral Neuroplasticity Task | measurement of electrical patterns in the brain while subject is performing behavioral task to measure basic neuroplasticity | Timepoints: at baseline and 1 and/or 7 days after infusion. |
| New Haven |
| Connecticut |
| 06519 |
| United States |
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Education (years) | Mean | Standard Deviation | years |
|
| Baseline Comorbidities | Count of Participants | Participants |
|
ketamine IV; 0.5 mg/kg over 40 minutes Ketamine: 1 single dose of IV ketamine |
|
|
| Primary | Change in Suicidality as Measured by the Columbia Suicide Severity Rating Scale (C-SSRS) | Suicide Rating Scale from 1-5; higher numbers indicate increased suicidal thinking. | Intention to treat. | Posted | Least Squares Mean | Standard Error | score on a scale | Timepoints will be baseline, 1hr post-infusion and at 1, 3, 7, 14, & 28 days after infusion. |
|
|
|
| Primary | Change in Suicidality as Measured by Item-12 on the Quick Inventory of Depressive Symptomatology (QIDS SR-16) | The Quick Inventory of Depressive Symptomatology (QIDS SR-16) is a a self-report measure of depression. Each item is scored from 0-3. Higher scores denote more severe load of depressive symptoms. Item 12 measures thoughts of death or suicide from 0 (no thoughts) to 3 (specific suicide plan or action.). Presented is the mean score across items with a range of 0 to 3 where the higher score indicates greater depressive symptoms. Outcome description was updated at the time of results entry. | Intention to treat. | Posted | Least Squares Mean | Standard Error | score on a scale | Timepoints will be baseline, 1hr post-infusion and at 1, 3, 7, 14, & 28 days after infusion. |
|
|
|
| Primary | Change in Suicidality as Measured by Item 9 on Beck Depression Inventory | When the test is scored, a value of 0 to 3 is assigned for each answer and then the total score is used to quantify the participant's degree of depression from 0 = no depression to 63 = maximally severe depression. Item 9 measures degree of suicidal thoughts or wishes from 0 = no thoughts to 3 = suicidal intent. | Intention to treat. | Posted | Least Squares Mean | Standard Error | units on a scale | Timepoints will be baseline, 1hr post-infusion and at 1, 3, 7, 14, & 28 days after infusion. |
|
|
|
| Secondary | Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score | The MADRS scale measures the depression level of a participant. The total score was derived by adding the scores of the following 10 items: 1, Apparent sadness; 2, Reported sadness; 3, Inner tension; 4, Reduced sleep; 5, Reduced appetite; 6, Concentration difficulties; 7, Lassitude; 8, Inability to feel; 9, Pessimistic thoughts; 10, Suicidal thoughts. Each item was scored using a scale of 0 to 6 (a higher score indicates increased severity). The maximum total score is 60; 0, no depression; 60, severely depressed. | Intention to treat. | Posted | Least Squares Mean | Standard Error | score on a scale | Timepoints will be baseline, 1hr post-infusion and at 1, 3, 7, 14, & 28 days after infusion. |
|
|
|
| Secondary | Change in Beck Depression Inventory Score | The Beck Depression Inventory (BDI) consisted of twenty-one questions about how the subject has been feeling in the last week. Each question has a set of at least four possible answer choices, ranging in intensity. When the test is scored, a value of 0 to 3 is assigned for each answer and then the total score is used to quantify the participant's degree of depression from 0 = no depression to 63 = maximally severe depression. | Intention to treat. | Posted | Least Squares Mean | Standard Error | score on a scale | Timepoints will be baseline, 1hr post-infusion and at 1, 3, 7, 14, & 28 days after infusion. |
|
|
|
| Secondary | Change in Beck Anxiety Inventory Score | The Beck Anxiety Inventory (BDI) consisted of twenty-one questions about how the subject has been feeling in the last week. Each question has a set of at least four possible answer choices, ranging in intensity. When the test is scored, a value of 0 to 3 is assigned for each answer and then the total score is used to quantify the participant's degree of anxiety from 0 = no anxiety to 63 = maximally severe anxiety. | Intention to treat. | Posted | Least Squares Mean | Standard Error | score on a scale | Timepoints will be baseline, 1hr post-infusion and at 1, 3, 7, 14, & 28 days after infusion. |
|
|
|
| Secondary | Change in Zanarini Rating Scale for Borderline Personality Disorder | A dimensional self-report measure of BPD symptoms that consists of 9 items scored on a 4 point likert scale. Scores range of 0 = minimally symptomatic to 28 = maximally symptomatic for symptoms of Borderline Personality Disorder. Originally, 1hr post-infusion was included as a time frame but this was not collected at this time frame. | Intention to treat. | Posted | Least Squares Mean | Standard Error | score on a scale | Timepoints will be baseline and at 1, 3, 7, 14, & 28 days after infusion. |
|
|
|
| Secondary | Change in Preferred Distance in Stop-distance Paradigm (SDP) | The stop-distance paradigm is a measure of preferred interpersonal distance (PID). Subjects begin the task standing face-to-face and 6 feet away from a test confederate. On each of 3 trials, the confederate slowly approaches the subject. The subjects are instructed to say "stop" to indicate their 1) preferred conversational distance, then a closer distance 2) "if you start to feel uncomfortable". After each "stop", toe to toe distance is measured using a tape measure, and mean PID for the three trials is computed separately for conversational and uncomfortable distance. A computerized version of the task may also be implemented for remote visits and administered in place of the in-person task. | Intention to treat. | Posted | Least Squares Mean | Standard Error | distance in inches | Timepoints will be at baseline and 3, 7, 14, 28 days after infusion |
|
|
|
| Secondary | Change in Behavior in the Economic Trust Game - Cooperation | The trust game is a multi-round economic exchange game. There are two roles in the game: investor and trustee. Study participants will play as the trustee. Each round, the investor is given a set number of points and can send any amount to the trustee. The investment triples and the trustee decides how much to repay the investor. Outcome measures are cooperation (amount returned to the investor) and coaxing (amount returned to investor on trials when poor prior returns from trustee have led investor to decrease investment). Cooperation was used as part of the evaluation in this study- coaxing was not. Outcome measure description was updated at the time of results entry. | Intention to treat. | Posted | Least Squares Mean | Standard Error | proportion of amount returned | Timepoints will be at baseline and 3, 7, 14, 28 days after infusion |
|
|
|
| Secondary | Change in Social Adjustment Scale Self Report (SAS-SR) Short Version Score | This questionaire measures expressive and instrumental performance over the past two weeks in six role areas: (1) work, either as a paid worker, unpaid homemaker, or student, (2) social and leisure activities, (3) relationships with extended family, (4) role as a marital partner, (5) parental role, and (6) role within the family unit, including perceptions about economic functioning.Each question is rated on a five-point scale from which role area means and an overall mean can be obtained, with higher scores denoting greater impairment. Role areas not relevant to the respondent can be skipped. Overall means are based on all items completed by the respondent. Scores range from 0 = no difficulties to 125 = broad difficulties in multiple domains. An overall adjustment | Intention to treat. | Posted | Least Squares Mean | Standard Error | score on a scale | Timepoints will be at baseline and 3, 7, 14, 28 days after infusion |
|
|
|
| Secondary | Change in Brief Pain Inventory Score - Intensity | Self report inventory that assesses intensity of pain and its interference with everyday life. Intensity: pain severity as measured by a 0 to 10 visual analogue scale. 0 = no pain, 10 = worst pain imaginable. Interference score: Interference as measured by a 0 to 10 numerical rating scale. 0 = does not interfere, 10 = completely interferes | Intention to treat. | Posted | Least Squares Mean | Standard Error | score on a scale | Timepoints will be at baseline, and post-infusion 1hr, and days 1, 3, 7, 14, & 28. |
|
|
|
| Secondary | Change in Brief Pain Inventory Score - Interference | Self report inventory that assesses intensity of pain and its interference with everyday life. Intensity: pain severity as measured by a 0 to 10 visual analogue scale. 0 = no pain, 10 = worst pain imaginable. Interference score: Interference as measured by a 0 to 10 numerical rating scale. 0 = does not interfere, 10 = completely interferes | Intention to treat. | Posted | Least Squares Mean | Standard Error | score on a scale | Timepoints will be at baseline, and post-infusion 1hr, and days 1, 3, 7, 14, & 28. |
|
|
|
| Secondary | Change in Clinician-Administered Dissociative States Scale (CADSS) Score | This scale captures the range of possible subjective side effects of ketamine or Midazolam. This consists of 23 questions and scores for each question range from 0-4. The maximum score is 92 with higher scores indicating more dissociative symptoms. | Intention to treat. | Posted | Least Squares Mean | Standard Error | score on a scale | Timepoints: pre- infusion, during infusion +20, +40 minutes, and post-infusion 40 minutes. |
|
|
|
| Secondary | Change in Adverse Events | Adverse events were tracked in a log of treatment emergent adverse events, EKG, pulse oximetry, vital signs. A count of any treatment emergent adverse events is presented through Day 28. The outcome measure description as updated when results were entered. | Posted | Count of Participants | Participants | Timepoints: Continuous monitoring throughout infusion; post-infusion days 1, 3, 7, 14, 28. |
|
|
|
| Secondary | Change in 'Reading the Mind in the Eyes' Test (RMET) Score | The RMET is an advanced test of theory of mind. It is widely used to assess individual differences in social cognition and emotion recognition across different groups and cultures. This is a score from 0-36 where higher score indicates better performance. | Intention to treat. | Posted | Least Squares Mean | Standard Error | score on a scale | Timepoints: at baseline and 3, 7, 14, 28 days after infusion. |
|
|
|
| Secondary | Change in Brief Psychiatric Rating Scale (BPRS) Total Scores | BPRS is an 18-item clinician rated scale with 11 general symptom items, 5 positive-symptom items, and 2 negative symptom items scored on a 7-point scale (1=not present and 7=extremely severe), with higher score indicating greater severity of symptom. Total possible score range=18 to 126. | Intention to treat. | Posted | Least Squares Mean | Standard Error | score on a scale | Timepoints: pre-infusion, during infusion +20, +40 minutes, post-infusion +40 minutes |
|
|
|
| Secondary | Change in Beck Suicide Scale Total Score | The Beck Suicide Scale is a 23 item self report scale with items to specifically assess the presence and intensity of thoughts and actions related to suicidality. Each item response is on a 3 point likert (0-2) for each of 21 items, so possible totals range from 0-42. Higher scores indicate higher suicidality. The description was updated when results were entered. | Intention to treat. | Posted | Least Squares Mean | Standard Error | score on a scale | Timepoints will be baseline, 1hr post-infusion and at 1, 3, 7, 14, & 28 days after infusion. |
|
|
|
| Other Pre-specified | Change in Bias Scores on the Implicit Association Tests (IAT) of Death, Escape and Self Harm Imagery. | The Implicit Association Test measures implicit automatic associations by tracking the speed at which participants associate different groups of words. The scale is delivered electronically using an open-source software. Three distinct IATs will be administered to assess participant's implicit associations with death, escape, and self harm imagery respectively. | Not Posted | Timepoints: at baseline and 1, 3, 7, 28 days after infusion. | Participants |
| Other Pre-specified | Change in Resting State Electroencephalography (EEG) | measurement of electrical patterns in the brain while subject is at rest with eyes open looking at fixation cross | Not Posted | Timepoints: at baseline and 1 and/or 7 days after infusion. | Participants |
| Other Pre-specified | Change in Electroencephalography (EEG) Signal During Behavioral Neuroplasticity Task | measurement of electrical patterns in the brain while subject is performing behavioral task to measure basic neuroplasticity | Not Posted | Timepoints: at baseline and 1 and/or 7 days after infusion. | Participants |
| 0 |
| 12 |
| 0 |
| 12 |
| 7 |
| 12 |
| EG001 | Low Dose Ketamine | ketamine IV; 0.5 mg/kg over 40 minutes Ketamine: 1 single dose of IV ketamine | 0 | 10 | 0 | 10 | 6 | 10 |
| Blurry/double vision | Nervous system disorders | Systematic Assessment |
|
| Jerky muscle movements | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Nausea or vomiting | Gastrointestinal disorders | Systematic Assessment |
|
| Diarrhea | Gastrointestinal disorders | Systematic Assessment |
|
| Hallucinations/Misperceptions | Nervous system disorders | Systematic Assessment |
|
| Headaches | Nervous system disorders | Systematic Assessment |
|
| Fatigue/Unsteadiness | Nervous system disorders | Systematic Assessment |
|
| Increased thirst | Endocrine disorders | Systematic Assessment |
|
| Body pain | Nervous system disorders | Systematic Assessment |
|
Not provided
Not provided
Not provided
| D001519 |
| Behavior |
| D006838 |
| Hydrocarbons |
| D009930 | Organic Chemicals |
| D001569 | Benzodiazepines |
| D001552 | Benzazepines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| Day 1 post-infusion |
|
| Day 3 post-infusion |
|
| Day 7 post-infusion |
|
| Day 14 post-infusion |
|
| Day 28 post-infusion |
|
| Day 1 post-infusion |
|
| Day 3 post-infusion |
|
| Day 7 post-infusion |
|
| Day 14 post-infusion |
|
| Day 28 post-infusion |
|
| Day 1 post-infusion |
|
| Day 3 post-infusion |
|
| Day 7 post-infusion |
|
| Day 14 post-infusion |
|
| Day 28 post-infusion |
|
| Day 1 |
|
| Day 3 |
|
| Day 7 |
|
| Day 14 |
|
| Day 28 |
|
| Day 1 |
|
| Day 3 |
|
| Day 7 |
|
| Day 14 |
|
| Day 28 |
|
| Day 1 |
|
| Day 3 |
|
| Day 7 |
|
| Day 14 |
|
| Day 28 |
|
| Day 3 |
|
| Day 7 |
|
| Day 14 |
|
| Day 28 |
|
| Day 7 |
|
| Day 14 |
|
| Day 28 |
|
| Day 7 |
|
| Day 14 |
|
| Day 28 |
|
| Day 7 |
|
| Day 14 |
|
| Day 28 |
|
| Day 1 |
|
| Day 3 |
|
| Day 7 |
|
| Day 14 |
|
| Day 28 |
|
| Day 1 |
|
| Day 3 |
|
| Day 7 |
|
| Day 14 |
|
| Day 28 |
|
| 40 minutes (during infusion) |
|
| 80 minutes (post infusion) |
|
| Day 7 |
|
| Day 14 |
|
| Day 28 |
|
| 40 Minutes (during infusion) |
|
| 80 Minutes (post infusion) |
|
| Day 1 |
|
| Day 3 |
|
| Day 7 |
|
| Day 14 |
|
| Day 28 |
|